Document is current
Any future updates will be listed below
-
Authors
Decker, Thomas https://orcid.org/0000-0003-3814-8775
Marschner, Norbert
Muendlein, Axel
Welt, Anja
Hagen, Volker
Rauh, Jaqueline
Schröder, Helge
Jaehnig, Peter
Potthoff, Karin
Lerchenmüller, Christian
-
Funding
Funding for this research was provided by:
Novartis, Germany
- License Information
-
More Information
Article History
Received: 2 May 2019
Accepted: 13 May 2019
First Online: 21 May 2019
Compliance with ethical standards
:
: TD: Honoraria (advisory board): Novartis and Celgene. NM: Honoraria and travel expenses: Novartis; Employment/leadership position and share ownership: iOMEDICO AG. AW: Advisory boards: Astra Zeneca, Novartis, Roche, Eisal, Pfizer, Amgen, Lilly; Fees: COCS GmbH, iOMEDICO AG, Interplan AG; Funding of scientific program: Novartis; Stocks, other financial relationships: None. VH: Honoraria (travel and meeting expenses): Roche, Amgen, Pfizer, Celgene, BMS, FomF, Janssen Cilag, iOMEDICO AG, Gilead; Consulting role: Roche; Share ownership: BMS, Johnson & Johnson. AM, JR, HS, PJ, KP, CL declare no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
